In conclusion, we have identified that UCA1 over-expression was significantly associated with poor outcome of NSCLC patients with acquired resistance to EGFR-TKIs and the impact of over-expression of UCA1 on PFS for patients with acquired resistance to EGFR-TKIs was from non-T790M subgroup. The gene discussed is UCA1; the disease is non-small cell lung carcinoma.